Articles tagged with Crisprs
Researchers have successfully corrected the genetic mutation responsible for Duchenne muscular dystrophy using CRISPR gene editing in muscle stem cells. The edited cells regenerated and produced dystrophin, suggesting a potential method for lifelong correction of the disorder.
The National Institutes of Health has granted $2.23 million in funding to develop statistical and computational methods for genome-wide CRISPR/Cas9 screening. The goal is to improve functional gene identification, analyze non-coding elements, and study genetic interactions, with potential applications in cancer research.
Researchers created a deformable nanolipogel-based delivery system for CRISPR knockout of oncogene Lcn2, reducing tumor growth by 77% in human and mouse models. The delivery method shows promise as a precise therapeutic tool for treating triple-negative breast cancer.
A new CRISPR gene editing system, encapsulated in a nanolipogel, effectively targets and knocks out the Lcn2 oncogene, curbing tumor growth in mice, providing a potential genetic treatment for triple-negative breast cancer.
The CRISPR Journal has published new articles on iCas9, a tool that enables precise gene editing without DNA breakage. Researchers also developed BEAT, a computational program to quantify base editing outcomes. Additionally, the journal reported on identifying genetic vulnerabilities in cancer cells via CRISPR-Cas9.
Researchers at UCSF and NIH create a new CRISPR technique that allows them to systematically alter gene activity in human neurons, enabling the study of neurological diseases. They discovered that housekeeping genes behave differently in neurons and stem cells, suggesting that these differences may play important roles in disease.
RESCUE, a new CRISPR platform, allows for targeted RNA edits previously impossible, offering a critical gap in the toolbox for treating diverse genetic changes. The technology can modulate protein activity by targeting phosphorylation sites, providing a reversible alternative to DNA-level modifications.
The University of Maryland's Yiping Qi reviews the current state and future of CRISPR technology in crops, suggesting applications beyond traditional gene editing. He aims to enhance traditional breeding techniques with CRISPR to ensure global food and nutritional security.
The Taniguchi Lab at MPFI has developed a novel protocol combining laser microdissection with single-cell genotyping to accurately link observed phenotypes to underlying genetics. This approach enables the reliable determination of exact genetic causes, particularly for genes in the brain that have subtle effects.
Scientists have captured atomic-level images of active CRISPR enzyme Cas9, providing new structural information on its mechanism. The images show how the enzyme cuts DNA strands and reveals the importance of domain movement during reaction, which could lead to improved genome-editing tools.
Researchers have developed a novel CRISPR-based platform called SHERLOCK that enables the detection and quantification of plant genes. The platform is rapid, portable, and low-cost, with high multiplexing capability, making it an important tool for agriculture in detecting pathogens or pests and in plant breeding.
Researchers have developed a rapid CRISPR-Cas13 detection system for agricultural applications, enabling trait screening and pest surveillance. A new library-based assay predicts Cas9 specificity, addressing off-target effects in gene editing therapies.
A proof-of-principle study shows that gold nanoparticles loaded with CRISPR safely and effectively edited blood stem cells in lab models of HIV and inherited blood disorders. The researchers found that the Cas12a protein partner delivered precise genetic edits, which were maintained for eight weeks after injection.
Researchers have identified a single gene, Lsdia1, responsible for snail shell coiling in a species of freshwater snail. The study reveals that this gene controls left-right asymmetry from the earliest stages of development.
BioBits Health, a Northwestern University-led project, introduces CRISPR and antibiotic resistance to high school students. Students perform experiments using freeze-dried cell-free reactions, visualizing DNA editing and drug resistance, and exploring ethics.
A new bioinformatics tool analyzes CRISPR pooled screen data to identify candidate genes involved in diseases, outperforming existing methods. The web-based tool is quicker and more user-friendly, empowering non-bioinformaticians to analyze data.
Researchers at Arizona State University have developed a method to render the CRISPR-Cas9 gene editing tool 'immunsilent', allowing for reliable and stealthy gene repair. This breakthrough brings CRISPR closer to safe clinical application, addressing key safety concerns.
A breakthrough CRISPR gene-editing tool allows for the simultaneous execution of multiple edits in DNA extracted from human cells. This technology, developed by the Gene Editing Institute and licensed to NovellusDx, can rapidly reproduce an individual patient's cancer tumor genetic features and identify driver mutations.
The CRISPR Journal publishes research on gene editing technologies, including base editors that enable precise base substitutions without DNA cleavage. A new method for multiplex site-directed mutagenesis also offers great promise for studying gene function.
A team of scientists at the Gladstone Institutes has developed a reliable method to identify potential off-target effects in therapeutically relevant cell types. The DISCOVER-Seq technique uses DNA repair factors to pinpoint exact sites where CRISPR cuts occur, enabling more accurate genome editing.
Biomedical engineers at Duke University developed a method to improve CRISPR accuracy by adding a short tail to the guide RNA, creating a 'lock' that prevents off-target activity. The approach increases accuracy by an average of 50-fold across five different CRISPR systems.
Scientists at UC San Diego developed a new CRISPR-based 'allelic drive' to selectively swap genetic variants, allowing precise editing of specific traits in populations. The technology has potential applications in agricultural pests, disease-carrying insects, and conservation efforts.
A new CRISPR-Cas3 tool has been developed for long-range DNA editing in human cells, allowing scientists to target and delete large expanses of DNA. This technique harnesses a different type of CRISPR system than the widely used Cas9 tools, enabling precise control over DNA degradation.
Researchers are exploring RNA editing as a way to treat diseases without permanent genetic changes. This approach uses an enzyme called ADAR to make precise edits to RNA, which can be reversible and avoid the risks of CRISPR.
Researchers have developed a CRISPR-based graphene biosensor that enables digital detection of DNA without amplification, allowing for fast and accurate genetic mutation testing. The system uses CRISPR's genome-searching capability and graphene's sensitivity to detect target genes without amplification.
A new CRISPR-based device, CRISPR-Chip, can detect specific genetic mutations in a matter of minutes. The device uses graphene transistors to scan DNA samples and report results electronically, bypassing the need for polymerase chain reaction amplification.
Researchers have discovered how viruses evade detection by bacteria using a molecular decoy that tricks the CRISPR defense. This breakthrough expands scientists' understanding of viral strategies and raises possibilities for crafting anti-CRISPRs in the lab.
Researchers at UT Southwestern Medical Center discovered that adjusting CRISPR dosages can significantly improve dystrophin production in edited genes. The optimal ratio of components changed based on the DNA sequence being edited, paving the way for optimized gene therapies for other diseases.
Researchers at IBS have identified the mistake-rate of DNA editing tools using CRISPR and adenine base editors. The study reveals that ABE7.10, a widely used gene engineering tool, has an average of 60 off-target mistakes in the human genome.
A new CMP-fusion strategy called CRISPR-chrom enhances CRISPR-Cas9 genome editing efficiency, especially at previously difficult-to-target sites. The approach demonstrates a substantial increase in CRISPR-Cas9 activity with no notable increase in off-target effects.
The CRISPR Journal announces publication of its February 2019 issue, featuring studies on strain tracking, single-step genome editing, and chromatin modulating motifs. Researchers discuss advancements in CRISPR technology and its applications.
Researchers at Duke University found that a single CRISPR treatment can safely correct genetic disease for over a year, despite immune responses. The study suggests approaches to address potential challenges and potentially deliver the therapy to infants or restrict Cas9 expression.
Researchers at IDIBELL have developed Nested CRISPR, a cloning-free method for genome editing using long DNA fragments. The technique involves two steps: inserting a small portion of the fragment into the genome and then using it as a
Researchers have developed two molecular safeguards to prevent accidental spread of CRISPR gene drives in the lab. Synthetic target site drive and split drive strategies show similar performance to standard drives, making them suitable substitutes for early gene-drive research.
A research team has identified and overcome a barrier in CRISPR gene editing that may lay the foundation for sustained treatments using the technique. By increasing the quantity of 'flags' in CRISPR, they were able to extend the effectiveness of treatment from three months to 18 months in mice with Duchenne muscular dystrophy.
The CRISPR Journal publishes outstanding research on all aspects of CRISPR and gene editing. Two new articles explore the ethics of germline editing and the use of alternative PAM sequences for mouse genome editing.
A team of UD engineers has developed a method to use CRISPR/Cas9 technology for conditional gene regulation, introducing a new functionality to the technology. This allows scientists to precisely target and edit DNA within living cells, which could help correct inherited diseases.
Researchers at the Francis Crick Institute discovered simple rules that determine the precision of CRISPR/Cas9 genome editing in human cells. By analyzing hundreds of edits, they found predictable patterns behind the technology, allowing for greater precision and efficiency.
Researchers at UCSF developed CRISPRa, a modified version of the gene-editing tool that activates appetite-suppressing genes without making cuts to the genome. This approach prevented severe obesity in genetically engineered mice with only one functional copy of certain genes.
Researchers have developed a deeper understanding of the CRISPR-Cas12a mechanism, enabling fine-tuning of the gene-editing process. By mapping the molecular structure and sequence of events, scientists can optimize the technology to achieve desired effects while minimizing side effects.
The CRISPR genome editing technique is revolutionizing plastic and reconstructive surgery with potential advances in craniofacial malformations, therapeutic skin grafts, and rejection-free transplants. Many challenges remain, including off-target effects, FDA regulation, and high costs.
Researchers have developed a new Cas9 enzyme that can target almost half of the genome's locations, significantly expanding its potential use. This could enable editing of many more disease-specific mutations, including those responsible for sickle cell anemia.
Researchers developed a novel technology to analyze hundreds of genes at single cell level, revealing critical immune system weakness in cancer. The Pro-Code technique identified disease-causing genes and potential drug targets for cancer immunotherapy.
Researchers found a compact CRISPR gene-editing machinery in ancient microbes, dubbed Cas14, which is smaller than other Cas proteins and has the potential to improve rapid diagnostic systems for infectious diseases, genetic mutations, and cancer. The discovery of Cas14 could provide a powerful addition to diagnostic tools.
The CRISPR Journal has published new articles on the development of a novel transcriptional activator system, CRISPR-Cas classification, patent appeals, anti-CRISPR proteins, and CRISPR-based art. Researchers have made significant advancements in understanding the complexities of CRISPR biology.
A multidisciplinary team applies CRISPR on a human liver-on-a-chip platform to identify biomarkers for toxicity and off-target effects. The study aims to predict liver tissue response in humans and develop effective gene editing tools.
Researchers at the Institute of Molecular Pathology Biomarkers at the University of Extremadura have discovered a new biomarker for Alzheimer's disease of sporadic origin, protein STIM1. A deficiency in this protein has been linked to calcium ion transport abnormalities, which can lead to neurodegeneration and cell death.
Researchers use CRISPR to tame the wild groundcherry, increasing fruit size and weight, and reducing weed growth habit. The modified plant also exhibits fewer instances of fruit drop, addressing food safety concerns.
Researchers at the Salk Institute have discovered the molecular structure of CRISPR-Cas13d, a promising enzyme for emerging RNA-editing technology. This breakthrough enables scientists to visualize how the enzyme guides and targets RNA, paving the way for new strategies to treat RNA-based diseases.
Researchers at UT Southwestern Medical Center used CRISPR genome-wide screening to identify the IFI6 gene as a potent antiviral gene targeting flaviviruses, including West Nile and Zika viruses. The study found that cells with a working IFI6 gene inhibited infection by these viruses in cell culture studies.
Researchers used CRISPR gene editing to restore dystrophin protein levels by up to 92% in dogs with Duchenne muscular dystrophy. The study provides strong indication of a potential lifesaving treatment for the disease, which affects one in 5,000 boys and leads to muscle and heart failure.
The CRISPR Journal publishes groundbreaking research on gene editing, including off-target effects in HIV therapy and the role of p53 in genome editing. The journal explores the ethics of CRISPR technology and its potential applications.
Researchers found that Cas12a is a more choosier enzyme than Cas9 due to its binding mechanism, making it less likely to edit the wrong part of the genome. This discovery could lead to improved gene editing in plants and animals with increased safety for human applications.
Researchers discovered that the Fanconi anemia DNA repair pathway plays a crucial role in fixing CRISPR breaks and increasing the efficiency of homology-directed repair. This new understanding could help boost CRISPR-Cas9 editing's success rates, particularly for treating diseases like sickle cell anemia.
Researchers discovered that phages cooperate to rapidly infect bacteria, overcoming destruction by CRISPR. The cooperation allows the first phage to sacrifice itself and produce anti-CRISPR compounds to neutralize some CRISPs, helping subsequent phages. This new model proposes a tipping point between numbers and speed of CRISPR and ant...
Researchers at University of California - San Francisco have successfully genetically reprogrammed human immune cells known as T cells without the need for viruses to insert DNA. The new CRISPR-based method employs electroporation and offers a robust molecular 'cut and paste' system to rewrite genome sequences in human T cells.
Recent studies have raised safety concerns over CRISPR's precision in human cell lines, but companies are forging ahead with therapies. The technology makes double-stranded breaks at specific sites in DNA to repair defective genes.
Researchers at University of Illinois Chicago discovered that persistent binding of the Cas9 protein to DNA causes CRISPR failure. To improve efficiency, they found that consistent strand selection forces RNA polymerases to collide with Cas9, knocking it off DNA.
Addgene has made over 100,000 CRISPR plasmids available to laboratories worldwide, democratizing genome editing research. This global access has enabled the advancement and flourishing of CRISPR technology.
The CRISPR Journal announces its third issue with novel techniques for long DNA delivery, correction of recessive genetic defects using endogenous repair, base editing quantification software, leveling the CRISPR playing field through accessible plasmid repositories, and insights into CRISPR's future by Editor-in-Chief Rodolphe Barrangou